Rohit Dhall
Department Chairperson
University of Arkansas for Medical Sciences
faculty
Neurology, College of Medicine
Research Areas
Is this your profile? Verify and claim your profile
Biography and Research Information
OverviewAI-generated summary
Rohit Dhall's research program focuses on the diagnosis and management of neurodegenerative disorders, including parkinsonism, dementias, dystonia, and tremor. His clinical research endeavors aim to develop novel diagnostics and therapeutics, alongside improving care delivery systems for individuals with neurological conditions. Dhall directs the UAMS Parkinson Foundation Comprehensive Care Center and the Cure PSP Center of Care, and co-directs the Multiple Systems Atrophy Center of Excellence at UAMS.
His recent publications include investigations into the safety and efficacy of various therapeutic agents for Parkinson's disease, such as NLY01 and continuous subcutaneous levodopa–carbidopa infusion (ND0612). He has also contributed to studies on treatments for chorea associated with Huntington's disease, including valbenazine and deutetrabenazine. Further research has explored interventions like Coordinated Reset Vibrotactile Stimulation for Parkinson's disease and novel levodopa formulations such as IPX203.
Dhall's work also encompasses understanding specific clinical phenotypes, such as olfactory deficits in the freezing of gait phenotype of Parkinson's disease. He has collaborated with Tuhin Virmani, Aliyah Glover, Lakshmi Pillai, and Krishna Nalleballe on multiple publications. Dhall holds an h-index of 28, with 99 total publications and 3,525 citations.
Research Overview
My clinical expertise in diagnosis and management of Neurodegenerative disorders, including parkinsonism, dementias, dystonia and tremor. My clinical research focuses on developing novel diagnostics and therapeutics, and developing and improving programs delivering care to people living with neurological illness. In addition to serving as Department Chair of Neurology, I direct UAMS' Parkinson Foundation Comprehensive Care Center, and CurePSP Center of Care, and co-direct the Multiple Systems Atrophy Center of Excellence at UAMS.
Metrics
- h-index: 28
- Publications: 99
- Citations: 3,525
Selected Publications
- Voice and Speech in Atypical Parkinsonian Disorders (2026) DOI
- Lessons Learned From a Delayed‐Start Trial of Modafinil for Freezing of Gait in Parkinson's Disease (2025) DOI
- A Qualitative Approach to Extract Diagnostic Patterns of Cognitive Impairment in Parkinson’s Disease (2025) DOI
- Transcutaneous Afferent Patterned Stimulation Provides Sustained Benefit in Essential Tremor (PROSPECT Study) (P1-5.002) (2025) DOI
- Safety and Efficacy of <scp>IPX203</scp> in Parkinson's Disease: The <scp>RISE‐PD Open‐Label</scp> Extension Study (2023) DOI
- Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial (2023) DOI
- A Randomized Phase 3 Study Comparing <scp>P2B001</scp> to its Components (Low‐Dose Extended‐Release Rasagiline and Pramipexole) and to Optimized Doses of Marketed Extended‐Release Pramipexole in Early Parkinson's Disease (2023) DOI
- Impedance trend from a symptomatic perielectrode cystic cavity following deep brain stimulation: illustrative case (2023) DOI
- Long-term Safety and Efficacy of IPX203 in Parkinson’s Disease Patients with Motor Fluctuations: A 9-Month Open-label Extension Trial (S32.006) (2023) DOI
- Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation (2023) DOI
- Conversion to Hybrid Deep Brain Stimulation System to Enable Multi‐Contact Fractionation Can be Therapeutic (2022) DOI
- Clinical Efficacy and Dosing of Vibrotactile Coordinated Reset Stimulation in Motor and Non-motor Symptoms of Parkinson's Disease: A Study Protocol (2021) DOI
- Olfactory Deficits in the Freezing of Gait Phenotype of Parkinson's Disease (2021) DOI
- Best Practices in the Clinical Management of Progressive Supranuclear Palsy and Corticobasal Syndrome: A Consensus Statement of the CurePSP Centers of Care (2021) DOI
- Electrophysiologic Mapping for Target Acquisition in Deep Brain Stimulation May Become Unnecessary in the Era of Intraoperative Imaging (2021) DOI
Research Interests
Neurodegenerative Disorder; Parkinsonism; Parkinson's Disease; Dementia; Tremor; Dystonia; Chorea Syndromes; Deep Brain Stimulation
Grants & Funding
- A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia (IRB 262548) AEON Biopharma, Inc. - Pass Through: PPD Investigator Services, LLC Principal Investigator
- 58 Week Open-label Trial of Tavapadon in Parkinson's Disease (TemPO-4 Trial) (IRB 262509) Cerevel Therapeutics, LLC - Pass Through: Syneos Health Principal Investigator
- No FP attached AbbVie Inc Principal Investigator
- A Multicenter, Open-Label Study to Evaluate the Safety and Tolerability of Tozadenant as Adjunctive Therapy in Levodopa- Treated Patients with Parkinson’s Disease Experiencing End of Dose “Wearing-Off” Biotie Therapies Inc. Principal Investigator
- A Randomized, Double-Blind, Placebo-Controlled Trial of IkT-148009 in Untreated Parkinson's Disease (IRB 274673) Inhibikase Therapeutics, Inc. - Pass Through: IQVIA, Inc. Principal Investigator
- PROSPECT: Prospective Study for Symptomatic Relief of ET with Cala Therapy (IRB 228403) Cala Health, Inc Principal Investigator
- No FP attached Neuraly - Pass Through: Rho, Inc Principal Investigator
- A Multicenter, Randomized, Active-Controlled, Double-Blind, Double-Dummy, Parallel Group Clinical Trial, Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison...(260930) NeuroDerm, Ltd. - Pass Through: Syneos Health Principal Investigator
Collaborators
Researchers in the database who share publications
Similar Researchers
Based on overlapping research topics